LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition

• Published in: Nature immunology Vol. 23; no. 7; pp. 1031 - 1041
• Main Authors: Ming, Qianqian, Celias, Daiana P., Wu, Chao, Cole, Aidan R., Singh, Srishti, Mason, Charlotte, Dong, Shen, Tran, Timothy H., Amarasinghe, Gaya K., Ruffell, Brian, Luca, Vincent C.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.07.2022; Nature Publishing Group
• Subjects: 631/250/1619/554; 631/250/251/1574; 631/250/516; 631/535/1266; Animals; Antibodies; Antigens, CD - metabolism; Biomedical and Life Sciences; Biomedicine; Cell activation; Crystal structure; Drug development; Epitope mapping; Fibrinogen; Histocompatibility Antigens Class II - metabolism; Humans; Immune checkpoint; Immunoglobulins; Immunology; Immunotherapy; Infectious Diseases; Interfaces; Ligands; Lymphocyte Activation; Lymphocyte Activation Gene 3 Protein; Lymphocytes; Lymphocytes T; Major histocompatibility complex; Mice; Protein structure; Proteins; Receptors, Immunologic
• ISSN: 1529-2908; 1529-2916
• DOI: 10.1038/s41590-022-01238-7

The immune checkpoint receptor lymphocyte activation gene 3 protein (LAG3) inhibits T cell function upon binding to major histocompatibility complex class II (MHC class II) or fibrinogen-like protein 1 (FGL1). Despite the emergence of LAG3 as a target for next-generation immunotherapies, we have little information describing the molecular structure of the LAG3 protein or how it engages cellular ligands. Here we determined the structures of human and murine LAG3 ectodomains, revealing a dimeric assembly mediated by Ig domain 2. Epitope mapping indicates that a potent LAG3 antagonist antibody blocks interactions with MHC class II and FGL1 by binding to a flexible ‘loop 2’ region in LAG3 domain 1. We also defined the LAG3–FGL1 interface by mapping mutations onto structures of LAG3 and FGL1 and established that FGL1 cross-linking induces the formation of higher-order LAG3 oligomers. These insights can guide LAG3-based drug development and implicate ligand-mediated LAG3 clustering as a mechanism for disrupting T cell activation. LAG3 inhibits T cell activation, but exactly how it does so has been unclear given a lack of structural information. Here the authors provide the crystal structure of the human and mouse LAG3 ectodomains, showing how they interact with known ligands and antibodies.